康希諾生物(06185.HK):嬰幼兒用吸附無細胞百(組分)白破聯合疫苗啟動III期臨牀試驗並完成首例受試者入組
格隆匯8月13日丨康希諾生物(06185.HK)公佈,公司的嬰幼兒用吸附無細胞百(組分)白破聯合疫苗(以下簡稱"嬰幼兒用DTcP")於近日正式啟動III期臨牀試驗,並完成首例受試者入組。
目前國內在售的共純化百白破疫苗(以下簡稱"DTaP")的製造過程使用百日咳抗原共純化的工藝,公司的嬰幼兒用DTcP為組分百白破疫苗,每種百日咳抗原可以單獨純化,以確定的比例配製,從而可以確保產品質量批間一致性,使產品的質量更加穩定。
截至目前,暫無國內疫苗廠商研發的組分百白破疫苗獲批上市,公司的嬰幼兒用DTcP定位即為進口替代。同時,該款疫苗的開發,也是青少年及成人用組分百白破疫苗和組分百白破聯合疫苗進一步研發的基礎。組分百白破疫苗產品組合將進一步豐富公司產品策略,提升公司核心競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.